Source: Shutterstock BioCryst Pharmaceuticals (NASDAQ:BCRX) stock is falling on Thursday after revealing the end of development for BCX9930. BCX9930 was in development alongside BCX10013 as a Factor D inhibitor. Patients in clinical trials benefitting from BCX9930 can continue treatment. The company also intends to switch them over to BCX10013 down the line. With the decision…

With a new month underway, investors may want to take a fresh look at various sectors. In the growth sector, a range of growth stocks continue to inspire confidence, despite what appears to be an environment of tapering in the coming months. With macroeconomic conditions outside of investors’ control, looking at top growth stocks with…

Investing in growth companies can help you create a significant amount of wealth from the stock market. In fact, to get rich, you really only need a few picks to become future multi-baggers. To that end, these seven growth stocks have the potential to skyrocket and take your portfolio to the next level. Growth companies…